In Pyo Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
In Pyo Hwang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Dentel
Department of Ophthalmology, Assistance Publique-Hôpitaux de Paris, Lariboisière Hospital, University of Paris Cité, Paris, France
1 shared publication Corentin Joffrois
Sorbonne Université, INSERM, CNRS, Institut de la Vision, F-75012 Paris, France
1 shared publicationCéline Nouvel-Jaillard
Sorbonne Université, INSERM, CNRS, Institut de la Vision, F-75012 Paris, France
1 shared publication- Deniz Dalkara
Institut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France
1 shared publication Diane Nava
Sorbonne Université, INSERM, CNRS, Institut de la Vision, F-75012 Paris, France
1 shared publication- Divya Ail
Sorbonne Université, INSERM, CNRS, Institut de la Vision
1 shared publication
Latest Publications
- Open Access
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (31) , eadg8163
Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinical studies. To address this unmet need, we generated three distinct inducible cynomolgus macaque models of RD. We developed two genetically targeted strategies using optogenetics and CRISPR-Cas9 to ablate rods and mimic rod-cone dystrophy. In addition, we created an acute model by physical separation of the photoreceptors and retinal pigment epithelium using a polymer patch. Among the three models, the CRISPR-Cas9–based approach was the most advantageous model in view of recapitulating disease-specific features and its ease of implementation. The acute model, however, resulted in the fastest degeneration, making it the most relevant model for testing end-stage vision restoration therapies such as stem cell transplantation.
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (31) , eadg8163
Open AccessInducible nonhuman primate models of retinal degeneration for testing end-stage therapies
The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinical studies. To address this unmet need, we generated three distinct inducible cynomolgus macaque models of RD. We developed two genetically targeted strategies using optogenetics and CRISPR-Cas9 to ablate rods and mimic rod-cone dystrophy. In addition, we created an acute model by physical separation of the photoreceptors and retinal pigment epithelium using a polymer patch. Among the three models, the CRISPR-Cas9–based approach was the most advantageous model in view of recapitulating disease-specific features and its ease of implementation. The acute model, however, resulted in the fastest degeneration, making it the most relevant model for testing end-stage vision restoration therapies such as stem cell transplantation.